Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.49M | $10.7M | $5.95M | $6.01M | $6.91M | $11.0M | $39.0M | $18.1M | $6.17M | $14.1M |
| Revenue growth | — | 617.6% | -44.4% | 1.1% | 15.0% | 58.9% | 255.1% | -53.5% | -66.0% | 128.2% |
| Operating income | -$492M | -$111M | -$89.8M | -$144M | -$57.8M | -$73.5M | -$65.5M | -$78.1M | -$76.3M | -$38.2M |
| Operating margin | -32973.8% | -1036.7% | -1510.2% | -2394.0% | -836.1% | -669.1% | -167.8% | -430.5% | -1236.7% | -271.0% |
| Net income | -$384M | -$84.4M | -$57.1M | -$154M | -$63.7M | -$76.2M | -$69.5M | -$72.8M | -$69.9M | -$33.5M |
| Net margin | -25765.5% | -788.9% | -959.8% | -2557.4% | -922.0% | -693.9% | -178.0% | -401.6% | -1133.0% | -237.9% |
| EPS (diluted) | -$7.24 | -$1.56 | -$1.21 | -$2.89 | -$1.00 | -$0.83 | -$0.46 | -$0.44 | -$0.38 | -$0.17 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$57.9M | -$48.6M | -$67.9M | -$71.0M | -$51.4M | -$67.5M | -$35.4M | -$85.9M | -$64.8M | -$39.6M |
| Capital expenditures | $4.00M | $7.26M | $1.14M | $589K | $229K | $809K | $512K | $1.01M | $182K | $0.00 |
| Free cash flow | -$61.9M | -$55.9M | -$69.0M | -$71.6M | -$51.7M | -$68.3M | -$35.9M | -$86.9M | -$65.0M | -$39.6M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $23.4M | $54.3M | $36.9M | $31.8M | $52.3M | $109M | $30.8M | $26.3M | $36.3M | $18.0M |
| Total assets | $276M | $237M | $228M | $106M | $137M | $204M | $195M | $144M | $132M | $94.6M |
| Total liabilities | $72.9M | $54.7M | $27.7M | $32.8M | $35.1M | $35.0M | $58.6M | $38.4M | $34.3M | $18.0M |
| Long-term debt | — | — | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shareholders' equity | $203M | $182M | $200M | $72.7M | $102M | $169M | $137M | $106M | $97.4M | $76.6M |
| Retained earnings | -$653M | -$738M | -$805M | -$970M | -$1.05B | -$1.13B | -$1.20B | -$1.28B | -$1.35B | -$1.38B |
| Shares (wtd avg diluted) | 53.1M | 54.7M | 55.3M | 64.8M | 75.8M | 106M | 151M | 166M | 186M | 192M |
Every figure is extracted from Arbutus Biopharma Corp’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.